OR WAIT null SECS
March 02, 2015
The fast growth of the global biopharmaceutical market has prompted global pharmaceutical and biotechnology companies to increase their R&D investment in biologics.
While the optimization of a lyophilization cycle for a biologic relies on a well-characterized formulation, viscosity and aggregation after product reconstitution must also be carefully managed.
Protecting workers, patients, and the environment requires advanced technologies.
While the skin offers an alternative route of administration for local and systemic drug delivery, developing semi-solid dosage forms can be a challenge.
A General Chapter on mAbs will be published in USP-NF as biologics increase their role in healthcare.
It is vital that companies involved in the manufacturing and handling of cytotoxic drugs ensure that staff are given the highest possible levels of protection.
February 27, 2015
FDA announced that it would postpone a meeting that would be critical for the advancement of Celltrion’s Remicade biosimilar in the US.
February 25, 2015
Remsima will now be available for patients in 12 additional countries in the European Union.
Enclosures contain powders and particulates during hazardous drug manipulation.
February 23, 2015
Bristol-Myers Squibb announced that it reached an agreement to acquire Flexus Biosciences and has entered into a $309-million partnership with Rigel Pharmaceuticals.